COVID-19 vaccine short-term adverse events in the real-life family practice in Krakow, Poland

References

• Lim J, Broughan J, Crowley D, et al. COVID-19’s impact on primary care and related mitigation strategies: a scoping review. Eur J Gen Pract. 2021;27(1):166–175.
   PubMed Web of Science ®Google Scholar
• Windak A, Frese T, Hummers E, et al. Academic general practice/family medicine in times of COVID-19–perspective of WONCA Europe. Eur J Gen Pract. 2020;26(1):182–188.
   PubMed Web of Science ®Google Scholar
• Neves AL, Li E, Gupta PP, et al. Virtual primary care in high-income countries during the COVID-19 pandemic: policy responses and lessons for the future. Eur J Gen Pract. 2021;27(1):241–247.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine | FDA [Internet]. [cited 2022 Jul 25]. Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.
   Google Scholar
• EMA recommends first COVID-19 vaccine for authorisation in the EU | European Medicines Agency [Internet]. [cited 2022 Jul 25]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu.
   Google Scholar
• European Medicines Agency. Jcovden (previously COVID-19 Vaccine Janssen) [Internet]. [cited 2022 Jul 25]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jcovden-previously-covid-19-vaccine-janssen.
   Google Scholar
• European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca) [Internet]. [cited 2022 Jul 25]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca.
   Google Scholar
• European Medicines Agency. Comirnaty [Internet]. [cited 2022 Jul 25]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty#product-information-section.
   Google Scholar
• European Medicines Agency. Spikevax (previously COVID-19 Vaccine Moderna) [Internet]. [cited 2022 Jul 25]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax.
   Google Scholar
• Jędrzejczyk T, Balwicki Ł. Poland country snapshot: public health agencies and services in the response to COVID-19 [Internet]. 2022 [cited 2022 Jul 25]. Available from: https://eurohealthobservatory.who.int/news-room/articles/item/poland-country-snapshot-public-health-agencies-and-services-in-the-response-to-covid-19.
   Google Scholar
• National Institute of Public Health. Vaccine Adverse Events after vaccination against COVID-19 in Poland. [Niepożądane Odczyny Poszczepienne po szczepionkach przeciw COVID-19 w Polsce Raport za okres 27.12.2020 - 26.04.2021][Polish] [Internet]. 2021 [cited 2022 Jul 25]. Available from: https://www.pzh.gov.pl/wp-content/uploads/2021/05/Raport-NOP-do-26.04.2021_v1-2.pdf.
   Google Scholar
• Clemente-Suárez VJ, Navarro-Jiménez E, Simón-Sanjurjo JA, et al. Mis–dis information in covid-19 health crisis: a narrative review. Int J Environ Res Public Health. 2022;19(9):5321.
   PubMed Web of Science ®Google Scholar
• Linde K, Bergmaier C, Torge M, et al. The diversity of opinion among general practitioners regarding the threat and measures against COVID-19–cross-sectional survey. Eur J Gen Pract. 2021;27(1):176–183.
   PubMed Web of Science ®Google Scholar
• Callaghan T, Washburn D, Goidel K, et al. Imperfect messengers? An analysis of vaccine confidence among primary care physicians. Vaccine. 2022;40(18):2588–2603.
   PubMed Web of Science ®Google Scholar
• Our World in Data. Coronavirus (COVID-19) Vaccinations [Internet]. Covid-19 Vaccin. [cited 2022 Jul 25]. Available from: https://ourworldindata.org/covid-vaccinations.
   Google Scholar
• Deng L, Glover C, Dymock M, et al. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. Med J Aust. 2022;217(4):195–202.
   PubMed Web of Science ®Google Scholar
• Zeschick N, Warkentin L, Kühlein T, et al. Active monitoring of adverse reactions following COVID-19 and other vaccinations: a feasibility study as part of the CoVaKo project. Pilot Feasibility Stud. 2022;8(1):1–13. Available from: 10.1186/s40814-022-01088-y.
   PubMedGoogle Scholar
• Vasileiou E, Shi T, Kerr S, et al. Investigating the uptake, effectiveness and safety of COVID-19 vaccines: protocol for an observational study using linked UK national data. BMJ Open. 2022;12(2):e050062.
   PubMed Web of Science ®Google Scholar
• Dziedzic A, Riad A, Attia S, et al. Self-reported adverse events of COVID-19 vaccines in polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST project results in Central Europe. J Clin Med. 2021;10(22):5338.
   PubMed Web of Science ®Google Scholar
• Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P, et al. The incidence and severity of post-vaccination reactions after vaccination against covid-19. Vaccines. 2021;9(5):502.
   Web of Science ®Google Scholar
• Paczkowska A, Hoffmann K, Michalak M, et al. Safety profile of COVID-19 vaccines among healthcare workers in Poland. Vaccines. 2022;10(3):434.
   Web of Science ®Google Scholar
• Andrzejczak-Grządko S, Czudy Z, Donerska M. Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. 2021;25(12):4418–4421.
   PubMed Web of Science ®Google Scholar
• Li L, Robinson LB, Patel R, et al. Association of self-reported high-risk allergy history with allergy symptoms after COVID-19 vaccination. JAMA Netw Open. 2021;4(10):e2131034.
   PubMed Web of Science ®Google Scholar
• Syan SK, Gohari MR, Levitt EE, et al. COVID-19 vaccine perceptions and differences by sex, age, and education in 1,367 community adults in Ontario. Front Public Heal. 2021;9. DOI:10.3389/fpubh.2021.719665
   Web of Science ®Google Scholar
• Urakawa R, Isomura ET, Matsunaga K, et al. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study. BMC Infect Dis. 2022;22(1):179. Available from: 10.1186/s12879-022-07175-y.
   PubMed Web of Science ®Google Scholar
• Chen M, Yuan Y, Zhou Y, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 2021;10(1):94.
   PubMed Web of Science ®Google Scholar
• Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):173.
   PubMed Web of Science ®Google Scholar
• Iguacel I, Maldonado AL, Ruiz-Cabello AL, et al. Association between covid-19 vaccine side effects and body mass index in Spain. Vaccines. 2021;9(11):1321.
   Web of Science ®Google Scholar
• Tissot N, Brunel AS, Bozon F, et al. Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine. Vaccine. 2021;39(36):5087–5090.
   PubMed Web of Science ®Google Scholar